Loading
A phase 2 trial of Inavolisib, Enzalutamide, Abiraterone acetate in prostate cancer, run by Hoffmann-La Roche, now recruiting.
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT07287150 by Hoffmann-La Roche, with 100 participants planned, started 2026-03-11 and due to reach its primary completion in 2028-03-31. Interventions recorded: Inavolisib, Enzalutamide, Abiraterone, Docetaxel. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares PI3K, AKT and mTOR inhibitors, Docetaxel, Metastatic castration-resistant prostate cancer, Small-molecule kinase inhibitors.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Small-molecule kinase inhibitors.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Small-molecule kinase inhibitors.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.